LOS ANGELES–(BUSINESS WIRE)–#biomarkers–DeciBio Consulting LLC’s latest market report, “Spatial Biology Market Report, Second Edition: 2024-2029,” states that the global spatial biology market is predicted to reach $2.27B by 2029.
The second edition of DeciBio’s spatial biology market report takes a comprehensive look at the global spatial biology products and services market landscape, summarizing both present and future (2024-2029) use. Informed by a combination of primary research, secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of key segments (e.g., by customer type, products and services, technology type, plex level, application, therapeutic area, competitor, and geography). In addition, this report details market drivers (e.g., increased access and familiarity), moderators (e.g., high costs of instruments and reagents), trends (e.g., acceleration in the adoption of spatial transcriptomics), and profiles of top players in the space.
Spatial Biology is defined as the analysis of a target analyte(s) in tissue in a spatial context (i.e., the expression of the marker in the context of its location within the tissue and / or other markers) and is driven primarily by multiplex analysis of biomarkers. Academia has been the largest customer segment of spatial biology analysis to date. However, its use in biopharma translational research and clinical trials is increasing, as preliminary studies yield promising results and both the technologies and analytical pipelines become more accessible and validated. Continued advancements in scalability, standardization, and clinical utility are expected to drive growth across all stages of R&D.
|
Report Details |
|
|
Research Methods |
|
|
2028 Market Size |
$2.27 billion |
|
CAGR (2023-2028) |
21% |
|
Base Year |
2023 |
|
Forecast Period |
2024-2029 |
|
Market / Forecast Currency |
USD |
|
Report Coverage |
Market size, segmentation, and forecast; key market players and trends; assays and technologies; market drivers and moderators; competitive analysis |
|
Segments Covered |
|
Learn more about DeciBio’s Spatial Biology Market Report, Second Edition: 2024-2029: https://www.decibio.com/product/spatial-biology-market
Companies Profiled in the Report:
- 10x Genomics
- Advanced Cell Diagnostics
- Akoya Biosciences
- Leica Microsystems
- Lunaphore
- Nanostring
- Neogenomics
- Standard Biotools
- Ultivue
- Vizgen
Spatial Biology – Market Analysis:
Market Drivers
The spatial biology market is advancing rapidly, as excitement around the insights that can be derived from spatial readouts drives greater adoption across all customer segments. New instruments have increasingly higher plex and resolution capabilities, unlocking deeper insights and driving interest in the use of more sophisticated platforms. Improvements in the spatial workflow – most notably, a greater incorporation of automation – will be critical in the coming years as customers look to scale up their experiments and improve reproducibility. Similarly, the use of AI will have a significant impact on the data analysis portion of the workflow, enabling more advanced analysis capabilities within and across datasets.
Market Moderators
Though the market is poised for rapid growth, barriers persist that may moderate how quickly the market grows. One of the greatest barriers faced today is the high instrument and reagent costs, which limit the use of spatial analyses, particularly in high-volume studies. Reproducibility is another challenge the field faces. Spatial experiments have a lengthy and complicated workflow making it difficult to reproduce results across users, instruments, and assays. In addition, data showing clear clinical utility will be required in the coming years to justify expanded use of spatial technology. Lastly, access to quality tissue samples can be a limiting factor, as sample handling and storage can significantly influence tissue quality and some diseases lack routine biopsies.
About DeciBio:
DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating innovation in precision medicine.
Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.
Contacts
Rebecca Burnham
Rebecca.burnham@decibio.com
310.451.4510
